Skip to Content
Merck

S4317

SB 431542 hydrate

≥98% (HPLC), powder, inhibits activation of SMAD proteins

Synonym(s):

4-(5-Benzol[1,3]dioxol-5-yl-4-pyrldin-2-yl-1H-imidazol-2-yl)-benzamide hydrate, 4-[4-(1,3-Benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]-benzamide hydrate, 4-[4-(3,4-Methylenedioxyphenyl)-5-(2-pyridyl)-1H-imidazol-2-yl]-benzamide hydrate

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C22H16N4O3 · xH2O
CAS Number:
301836-41-9
Molecular Weight:
384.39 (anhydrous basis)
UNSPSC Code:
51111800
PubChem Substance ID:
24724609
NACRES:
NA.77
MDL number:
MFCD11045982

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

SB 431542 hydrate, ≥98% (HPLC), powder

SMILES string

O.NC(=O)c1ccc(cc1)-c2nc(-c3ccc4OCOc4c3)c([nH]2)-c5ccccn5

InChI

1S/C22H16N4O3.H2O/c23-21(27)13-4-6-14(7-5-13)22-25-19(20(26-22)16-3-1-2-10-24-16)15-8-9-17-18(11-15)29-12-28-17;/h1-11H,12H2,(H2,23,27)(H,25,26);1H2

InChI key

WQUIJVKNPYBZOF-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

solubility

DMSO: soluble 10 mg/mL
H2O: insoluble

originator

GlaxoSmithKline

storage temp.

−20°C

Quality Level

100

Application

SB-431542 was used to study the correlation of platelet-derived growth factor receptor B expression and TGF-β pathway activation in colorectal tumor cells. It was used to study the role of TGF-β signaling in modulation of extracellular matrix and myoblast differentiation.

Biochem/physiol Actions

Potent and selective inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors.
SB-431542 inhibits the TGF-β-mediated activation of SMAD proteins, expression of collagen and fibronectin, cell proliferation and cell motility. It does not inhibit kinases that are activated in response to serum or stress such as ERK, p38 or JNK.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

Sold for research purposes under agreement from Glaxo­Smith­Kline

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
037M4740V
045M4722V
104M4747V
063M4703V
062M4618V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mark D Hjelmeland et al.
Molecular cancer therapeutics, 3(6), 737-745 (2004-06-24)
Transforming growth factor-beta (TGF-beta) is a multifunctional cytokine that promotes malignant glioma invasion, angiogenesis, and immunosuppression. Antisense oligonucleotide suppression of TGF-beta(2) ligand expression has shown promise in preclinical and clinical studies but at least two ligands mediate the effects of
N J Laping et al.
Molecular pharmacology, 62(1), 58-64 (2002-06-18)
Transforming growth factor beta1 (TGF-beta1) is a potent fibrotic factor responsible for the synthesis of extracellular matrix. TGF-beta1 acts through the TGF-beta type I and type II receptors to activate intracellular mediators, such as Smad proteins, the p38 mitogen-activated protein
Gareth J Inman et al.
Molecular pharmacology, 62(1), 65-74 (2002-06-18)
Small molecule inhibitors have proven extremely useful for investigating signal transduction pathways and have the potential for development into therapeutics for inhibiting signal transduction pathways whose activities contribute to human diseases. Transforming growth factor beta (TGF-beta) is a member of
A Smad3 and TTF-1/NKX2-1 complex regulates Smad4-independent gene expression.
Isogaya K, Koinuma D, Tsutsumi S, et al.
Cell Research, 24(8), 994-1008 (2014)
Paola Bendinelli et al.
International journal of molecular sciences, 20(10) (2019-05-28)
Hepatocyte growth factor (HGF) and transforming growth factor β1 (TGFβ1) are biological stimuli of the micro-environment which affect bone metastasis phenotype through transcription factors, but their influence on the growth is scarcely known. In a xenograft model prepared with 1833
View All Related Papers

Related Content

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service